Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTJ4QE7)

• DTT Name: Matrix metalloproteinase-14 (MMP-14) DTT Info
• Gene Name: MMP14

Molecule-Related Drug & Molecule List

2 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[1]
BT1718	DMTXBUV	Solid tumour/cancer	2A00-2F9Z	Phase 1/2a	[2]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GM6001	DM7V9CT	Corneal ulcer	9A76	Discontinued in Phase 2	[3]

12 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2-(4-bromophenylsulfonamido)-N-hydroxyacetamide	DMY5STK	Discovery agent	N.A.	Investigative	[4]
2-(biphenyl-4-ylsulfonamido)-N-hydroxyacetamide	DM3PWK7	Discovery agent	N.A.	Investigative	[4]
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	DMCNV5J	Discovery agent	N.A.	Investigative	[5]
DX-2400	DMF9M06	Solid tumour/cancer	2A00-2F9Z	Investigative	[6]
IK-862	DMJA4UE	Discovery agent	N.A.	Investigative	[7]
MMI270	DM38N2K	Discovery agent	N.A.	Investigative	[8]
N-hydroxy-2-(4-methoxyphenylsulfonamido)acetamide	DM50NKS	Discovery agent	N.A.	Investigative	[4]
N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	DM4VADN	Discovery agent	N.A.	Investigative	[5]
PMID23631440C29e	DMM92IB	Discovery agent	N.A.	Investigative	[9]
SR-973	DMU48OD	Discovery agent	N.A.	Investigative	[10]
UK-356618	DM02FGH	Discovery agent	N.A.	Investigative	[11]
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	DM37C25	Discovery agent	N.A.	Investigative	[5]

References

• [1] Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4.
• [2] ClinicalTrials.gov (NCT03486730) BT1718 in Patients With Advanced Solid Tumours.. U.S. National Institutes of Health.
• [3] Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59.
• [4] Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule sheddi... J Med Chem. 2010 Mar 25;53(6):2622-35.
• [5] Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1638).
• [7] Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
• [8] Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
• [9] Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core. J Med Chem. 2013 Jun 13;56(11):4357-73.
• [10] Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
• [11] A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.